FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Alnylam Gains Expanded Label for Oxlumo

[ Price : $8.95]

FDA approves an Alnylam Pharmaceuticals supplemental NDA to expand the label for Oxlumo (lumasiran).

FDA Wants Makena Withdrawn While New Trial Conducted

[ Price : $8.95]

In arguing for its market withdrawal, an FDA briefing document says Covis Makena is not effective and has known risks.

Fresenius Recalls Ivenix Infusion Pump

[ Price : $8.95]

Fresenius Kabi recalls its Ivenix Infusion Systems large volume pump software due to a software design issue.

Ways to Improve FAERS Signal Review

[ Price : $8.95]

Yale University researchers say FDA should consider three ways to enhance the timely and robust assessment of drug safety signals ...

Boston Cell Standards IHControls Panel Cleared

[ Price : $8.95]

FDA clears a Boston Cell Standards 510(k) for its IHControls panel (HER2/ER/PR) for evaluating breast cancers.

AATD Consortium Partnership Launched

[ Price : $8.95]

CDER and CBER partner with the Critical Path Institute to plan for a consortium to facilitate clinical development programs for al...

FDA Steps to Harmonize with HHS Common Rule

[ Price : $8.95]

Two FDA officials describe steps the agency is taking to harmonize its oversight of clinical trials with the HHS Common Rule on pr...

Essure Postmarket Study Inadequate: FDA

[ Price : $8.95]

FDA says Bayer is making inadequate progress in a postmarket surveillance study of its Essure birth control device.

Lilly Fast Track for Obesity Drug

[ Price : $8.95]

FDA grants Eli Lilly a fast track designation for tirzepatide and its use for treating adults with obesity, or overweight with we...

Medical Device User Fee Rates Set

[ Price : $8.95]

Federal Register notice: FDA sets the medical device user fee rates and payment procedures for fiscal year 2023.